Prot #LAS-MD-45: Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Very Severe COPD (ASCENT COPD

Project: Research project

Project Details

StatusFinished
Effective start/end date4/14/144/14/18

Funding

  • DrugDev Inc. (Prot #LAS-MD-45)
  • AstraZeneca Pharmaceuticals LP (Prot #LAS-MD-45)